Anti-D immunoglobulin in Rh(D) negative volunteers: Clearance of Rh(D) positive red cells and kinetics of serum anti-D levels

Transfusion Clinique et Biologique

Volumn 5, Issue 3, 1998, Pages 180-188

  Stucki, M ^b   Schnorf, J ^b   Hustinx, H ^b   Gerber, H ^b   Lerch, P G ^b   Halabi, A ^a   Kleinbloesem, C H ^a   Morell, A ^b  

^a Clin Pharma Research AG   (Switzerland)

^b NONE

Author keywords

Anti D; Pharmacodynamics; Pharmacokinetics; Prophylaxis; Rh(D) immunization

Indexed keywords

RHESUS D ANTIBODY; RHESUS D ANTIGEN;

ARTICLE; BLOOD GROUP RHESUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; RHESUS IMMUNIZATION; RHESUS INCOMPATIBILITY;

EID: 0032105439     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1246-7820(98)80409-6     Document Type: Article

References (39)

1. 1 Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 9th ed. Oxford, London: Blackwell Scientific Publications, 1993
2. 2 Hughes-Jones NC, Mollison PL, Veall N. Removal of incompatible red cells by the spleen. Br J Haematol 1957 ; 3 : 125-33
3. 3 Engelfriet CP. The immune destruction of red cells. Transfus Med 1992 ; 2 : 1-6
4. 4 Kumpel BM. In vitro functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D. Vox Sang 1997 ; 72 : 45-51
5. 5 Gorick BD, Hughes-Jones NC. Relative functional binding activity of IgG1 and IgG3 anti-D in IgG preparations. Vox Sang 1991 ; 62 : 251-4
6. 6 Mattila PS, Seppala IJT, Eklund J, Makela O. Quantitation of immunoglobulin classes and subclasses in anti-Rh(D) antibodies. Vox Sang 1985 ; 48 : 350-6
7. 7 Prevention of Rhesus sensitization. WHO Technical Report Series, No 468. Geneva: World Health Organization; 1971
8. 8 Pollack W, Ascari WQ, Crispen JF, O'Connor RR, Ho TY. Studies on Rh prophylaxis: II. Rh immune prophylaxis after transfusions with Rh-positive blood. Transfusion 1971 ; 11 : 340-4
9. 9 Proceedings of the McMaster Conference on Prevention of Rh immunization. Vox Sang 1979 ; 36 : 50-64
10. 10 Schneider J. 4. Arbeitstagung zur Prophylaxe der Rh-Sensibilisierung mit Immunglobulin-anti-D (29.-30. Mai 1970, Bonn). Geburtshilfe Frauenheilkd 1971 ; 31 : 493-522
11. 11 Maroni ES. Die erweiterte Rhesusprophylaxe. Schweiz Rundsch Med Prax 1987 ; 76 : 1254-9
12. 12 Medical Research Council. Report of a working party on the use of anti-D immunoglobulin for the prevention of isoimmunization of Rh-negative women during pregnancy. Brit Med J 1974 ; 2 : 75-80
13. 13 Committee for Proprietary Medicinal Products (CPMP). Note for Guidance: core summary of product characteristics for human anti-D immunoglobulin. Brussels: Commission of the European Communities; 1992. DG III 3463/92-EN
14. 14 Consensus Conference on Anti-D Prophylaxis, April 8-9, Royal College of Physicians of Edinburgh, and Royal College of Obstetricians and Gynecologists (abstracts). Brit J Obstet Gynaecol 1997 ; 104 : 859-66
15. 15 Ness P, Manitove J, Snyder EL. Guidelines for the use of intravenous Rh immune globulin. A report of the AABB ad hoc intravenous Rh immune globulin committee. AABB News Briefs 1996 ; February : 2-3
16. 16 Stucki M, Moudry R, Kempf Ch, Omar A, Schlegel A, Lerch PG. Characterisation of a chromatographically purified anti-D immunoglobulin product. J Chromatogr B Biomed Appl 1997 ; 700 : 241-8
17. 17 World Health Organization Expert Committee on Biological Standardization. Forty-third report. Geneva: WHO; 1994. WHO Technical Report Series No 840
18. 18 Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992 ; 79 : 826-31
19. 19 Hustinx H. PEF: a new method for the quantification of Rh(D)-positive erythrocytes in Rh(D)-negative individuals by fluorescence technique [Poster]. ARC Reference Laboratory Conference; Boston; 1996
20. 20 Hustinx H, Eicher N. Present and Future of the Gel Test, DiaMed [Poster]. First International Symposium; Montreux, Switzerland; March 17-18, 1993
21. 21 Bowman JM, Friesen AD, Pollock JM, Taylor WE. WinRho: Rh immune globulin prepared by ion exchange for intravenous use. Can Med Assoc J 1980 ; 123 : 1121-5
22. 22 Jouvenceaux A, Adenot N, Berthoux F, Revol L. Gammaglobuline anti-D lyophilisée intraveineuse pour la prévention de l'immunisation anti-Rh. Prog Immunobiol Stand 1970 ; 4 : 291-5
23. 23 Smith GN, Griffith B, Mollison D, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1972 ; 1 : 1208-12
24. 24 Morell A, Schüren B, Ryser D, Hofer F, Skvaril F, Barandun S. In vivo behaviour of gammaglobulin preparations. Vox Sang 1980 ; 38 : 272-83
25. 25 Huchet J, Crégut R, Pinon F. Immunoglobulines anti-D. Efficacité comparée des voies intra-musculaire et intraveineuse. Rev Fr Transfus 1970 ; 13 : 231-42
26. 26 Mollison PL, Hughes-Jones NC. Clearance of Rh-positive cells by low concentrations of Rh antibody. Immunology 1967 ; 12 : 63-73
27. 27 Zipurski A, Israels LG. The pathogenesis and prevention of Rh immunization. Can Med Assoc J 1967 ; 97 : 1245-57
28. 28 Goodrick J, Kumpel B, Pamphilon D, Fraser I, Chapman G, Dawes B. Plasma half-lives and bioavailability of human monoclonal RhD antibodies BRAD-3 and BRAD-5 following intramuscular injection into RhD-negative volunteers. Clin Exp Immunol 1994 ; 98 : 17-20
29. 29 Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969 ; 13 : 1-110
30. 30 Chapman GE. A pharmacokinetic/pharmacodynamic model for the action of anti-D immunoglobulin in affecting circulatory clearance of RhD+ red cells. Transfus Med 1996 ; 6 : 227-33
31. 31 Bowman JM, Pollock JM. Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfus Med Rev 1987 ; 1 : 101-12
32. 32 Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970 ; 49 : 673-80
33. 33 Jouvenceaux A. Prévention de l'immunisation anti-Rh. Rev Fr Transfus 1971 ; 14 : 39-52
34. 34 Maroni E, Angst F. Der Stand der Rhesusprophylaxe in der Schweiz im Jahre 1985. Arch Gynecol 1986 ; 239 : 235-40
35. 35 Dudok de Wit C, Borst-Eilers E. Failure of anti-D immunoglobulin injection to protect against Rhesus immunization after massive foeto-maternal haemorrhage. Report of 4 cases. Brit Med J 1968 ; 1 : 152-4
36. 36 Hughes-Jones NC, Mollison PL. Failure of a relatively small dose of passively administered anti-Rh to suppress primary immunization by a relatively larger dose of Rh-positive red cells. Brit Med J 1968 ; 1 : 150-1
37. 37 Stern K, Davidson I, Masaitis L. Experimental studies on Rh immunization. Am J Clin Pathol 1956 ; 26 : 833-43
38. 38 Clarke CA, Donohue WTA, McConnell RB et al. Further experimental studies in the prevention of Rh haemolytic disease. Br Med J 1963 ; 1 : 979-84
39. 39 Freda VJ, Gorman JG, Pollack W. Successful prevention of experimental Rh sensitization in man with an anti-Rh gammaglobulin: a preliminary report. Transfusion 1964 ; 4 : 26-32